In a challenging market environment, Precigen Inc. (NASDAQ:PGEN) stock has reached a 52-week low, dipping to $0.83. This latest price level reflects a significant downturn for the company, which has experienced a 1-year change with a decline of -31.27%. Investors are closely monitoring the stock as it navigates through the pressures that have led to this low point, considering both the company's performance and broader market trends that have influenced this downward trajectory. The 52-week low serves as a critical indicator for shareholders and potential investors, marking the lowest price at which the stock has traded during the last year and setting a benchmark for its future performance.
In other recent news, Precigen Inc. has reported notable advancements in its PRGN-2012 gene therapy program for recurrent respiratory papillomatosis (RRP), with over half of the patients showing a complete response and a significant reduction in surgeries. The company is planning for a Biologics License Application (BLA) submission by the end of 2024, with potential commercialization in 2025. Precigen has also granted performance stock units (PSUs) to key executives, contingent upon meeting specific operational milestones related to PRGN-2012. The vesting of these units depends on a successful submission of a complete BLA to the U.S. Food and Drug Administration (FDA) and its subsequent approval by the end of 2026. In addition, Jeffrey Perez, Senior Vice President of Intellectual Property Affairs, is set to leave Precigen effective November 1, 2024. H.C. Wainwright, an independent analyst firm, has adjusted its price target for Precigen's shares to $4.00, maintaining a Buy rating. The firm's projections include an expectation of PRGN-2012 generating risk-adjusted revenue in 2026, estimated at $106 million, and growing to $521 million by 2030. These are among the recent developments in Precigen's strategic focus on PRGN-2012.
InvestingPro Insights
The recent downturn in Precigen Inc. (PGEN) stock is further illuminated by real-time data from InvestingPro. As of the latest quarter, the company's revenue stands at a modest $4.39 million, with a concerning revenue growth decline of 80.14% over the last twelve months. This aligns with an InvestingPro Tip indicating that analysts anticipate a sales decline in the current year.
The stock's current struggles are evident in its market performance metrics. InvestingPro data shows a 45.16% price decline over the past three months, corroborating the article's mention of the stock reaching a 52-week low. An InvestingPro Tip suggests that the stock's RSI indicates it may be in oversold territory, potentially signaling a point of interest for value investors.
Financially, Precigen faces significant challenges. The company is not profitable over the last twelve months, with a concerning gross profit margin of -1255.73%. An InvestingPro Tip warns that the company is quickly burning through cash, which could be a critical factor in its future stability and growth prospects.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Precigen, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.